263 results
8-K
EX-99.1
LLY
Lilly(Eli) & Co
30 Apr 24
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
7:04am
trial, which evaluated the efficacy and safety of donanemab in early symptomatic Alzheimer's disease;
The announcement that the multi-dose Kwikpen … pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto; safety or efficacy concerns
424B2
s6754csfpw934dgn
8 Feb 24
Prospectus for primary offering
4:51pm
424B2
dqfl1m5a 9lmhxaq
7 Feb 24
Prospectus for primary offering
8:12am
8-K
EX-99.1
y0b3sw8urq
6 Feb 24
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
7:04am
8-K
EX-99.1
8yawyfjmlq8d dm7
2 Nov 23
Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
7:02am
CORRESP
fh0yaevx679nvu gm
26 Oct 23
Correspondence with SEC
12:00am
UPLOAD
mqmvloj6vm7 p9t7fgq1
29 Sep 23
Letter from SEC
12:00am
CORRESP
3z71ni8ya gklory19h
20 Sep 23
Correspondence with SEC
12:00am
8-K
EX-99.1
r09ts 7um
8 Aug 23
Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements
7:01am
SC TO-T
EX-99
rjl7rh9p9x5s oefv
13 Jul 23
Third party tender offer statement
8:01am
8-K
EX-99.01
l8ksfsjhfjzyk49
27 Apr 23
Results of Operations and Financial Condition
7:02am
PX14A6G
lbg2koc
10 Apr 23
Letter to shareholders
4:51pm
8-K
EX-99
r11o9nncuc5i41 fka11
13 Dec 22
Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines
7:03am